Poor Agreement between Clinician Response Ratings and Calculated Response Measures in Patients with Chronic Graft-versus-Host Disease

被引:20
作者
Palmer, Jeanne M. [1 ]
Lee, Stephanie J. [2 ]
Chai, Xiaoyu [2 ]
Storer, Barry E. [2 ]
Flowers, Mary E. D. [2 ]
Schultz, Kirk R. [3 ]
Inamoto, Yoshihiro [2 ]
Cutler, Corey [4 ]
Pidala, Joseph [5 ]
Arora, Mukta [6 ]
Jacobsohn, David A. [7 ]
Carpenter, Paul A. [2 ]
Pavletic, Steven Z. [8 ]
Martin, Paul J. [2 ]
机构
[1] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[3] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[6] Univ Minnesota, Minneapolis, MN USA
[7] Childrens Natl Med Ctr, Washington, DC 20010 USA
[8] NCI, Bethesda, MD 20892 USA
关键词
Allogeneic hematopoietic cell transplantation; Chronic graft-versus-host disease; Response assessment; CONSENSUS DEVELOPMENT PROJECT; THERAPEUTIC RESPONSE; PHASE-II; CRITERIA; TRIALS;
D O I
10.1016/j.bbmt.2012.05.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In 2005, a National Institutes of Health consensus conference was held to refine methods for research in patients with chronic graft-versus-host disease, including proposed objective response measures and a provisional algorithm for calculating organ-specific and overall response. In this study, we used weighted kappa statistics to evaluate the level of agreement between clinician response ratings and calculated response categories in patients with chronic graft-versus-host disease. The study included 290 patients who had paired enrollment and follow-up visits. Based on a set of objective measures, 37% of the patients had an overall complete or partial response, whereas clinicians reported an overall complete or partial response rate of 71% (slight to fair agreement, weighted kappa 0.20). Agreement rates between calculated organ-specific responses and clinician-reported changes in skin, mouth, and eyes were fair to moderate (weighted kappa, 0.28-0.54). We conclude that for both overall and organ-specific comparisons, clinician response ratings did not agree well with calculated response categories. Possible reasons for this discrepancy include a high clinical sensitivity for detecting response, a clinical predisposition to recognize selective improvements as overall response, the large change in objective measures proposed to define response, and the high incidence of progressive disease based on new manifestations. Conclusions from prior literature reporting high overall response rates based on clinician judgment would not be supported if the provisional algorithm had been applied to calculate response. Our analysis also highlights the need to define an overall response measure that incorporates both patient-reported and objective measures and accurately reflects the outcome in patients with a mixed response in which one organ or site improves, whereas another shows new involvement. Biol Blood Marrow Transplant 18: 1649-1655 (2012) (C) 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1649 / 1655
页数:7
相关论文
共 21 条
  • [1] Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria
    Arai, Sally
    Jagasia, Madan
    Storer, Barry
    Chai, Xiaoyu
    Pidala, Joseph
    Cutler, Corey
    Arora, Mukta
    Weisdorf, Daniel J.
    Flowers, Mary E. D.
    Martin, Paul J.
    Palmer, Jeanne
    Jacobsohn, David
    Pavletic, Steven Z.
    Vogelsang, Georgia B.
    Lee, Stephanie J.
    [J]. BLOOD, 2011, 118 (15) : 4242 - 4249
  • [2] Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease
    Arora, M
    Wagner, JE
    Davies, SM
    Blazar, BR
    Defor, T
    Enright, H
    Miller, WF
    Weisdorf, DJ
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (05) : 265 - 273
  • [3] Busca A, 2003, HAEMATOLOGICA, V88, P837
  • [4] How I conduct a comprehensive chronic graft-versus-host disease assessment
    Carpenter, Paul A.
    [J]. BLOOD, 2011, 118 (10) : 2679 - 2687
  • [5] A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies
    Chen, George L.
    Arai, Sally
    Flowers, Mary E. D.
    Otani, Joanne M.
    Qiu, Jingxin
    Cheng, Ethan C.
    McMillan, Alex
    Johnston, Laura J.
    Shizuru, Judith A.
    Miklos, David B.
    [J]. BLOOD, 2011, 118 (15) : 4070 - 4078
  • [6] Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD
    Couriel, DR
    Hosing, C
    Saliba, R
    Shpall, EJ
    Anderlini, P
    Rhodes, B
    Smith, V
    Khouri, I
    Giralt, S
    de Lima, M
    Hsu, Y
    Ghosh, S
    Neumann, J
    Andersson, B
    Qazilbash, M
    Hymes, S
    Kim, S
    Champlin, R
    Donato, M
    [J]. BLOOD, 2006, 107 (08) : 3074 - 3080
  • [7] Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease
    Couriel, DR
    Saliba, R
    Escalón, MP
    Hsu, Y
    Ghosh, S
    Ippoliti, C
    Hicks, K
    Donato, M
    Giralt, S
    Khouri, IF
    Hosing, C
    de Lima, MJ
    Andersson, B
    Neumann, J
    Champlin, R
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2005, 130 (03) : 409 - 417
  • [8] Rituximab for steroid-refractory chronic graft-versus-host disease
    Cutler, Corey
    Miklos, David
    Kim, Haesook T.
    Treister, Nathaniel
    Woo, Sook-Bin
    Bienfang, Don
    Klickstein, Lloyd B.
    Levin, Jesse
    Miller, Katherine
    Reynolds, Carol
    Macdonell, Rebecca
    Pasek, Mildred
    Lee, Stephanie J.
    Ho, Vincent
    Soiffer, Robert
    Antin, Joseph H.
    Ritz, Jerome
    Alyea, Edwin
    [J]. BLOOD, 2006, 108 (02) : 756 - 762
  • [9] National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report
    Filipovich, AH
    Weisdorf, D
    Pavletic, S
    Socie, G
    Wingard, JR
    Lee, SJ
    Martin, P
    Chien, J
    Przepiorka, D
    Couriel, D
    Cowen, EW
    Dinndorf, P
    Farrell, A
    Hartzman, R
    Henslee-Downey, J
    Jacobsohn, D
    McDonald, G
    Mittleman, B
    Rizzo, JD
    Robinson, M
    Schubert, M
    Schultz, K
    Shulman, H
    Turner, M
    Vogelsang, G
    Flowers, MED
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (12) : 945 - 956
  • [10] EQUIVALENCE OF WEIGHTED KAPPA AND INTRACLASS CORRELATION COEFFICIENT AS MEASURES OF RELIABILITY
    FLEISS, JL
    COHEN, J
    [J]. EDUCATIONAL AND PSYCHOLOGICAL MEASUREMENT, 1973, 33 (03) : 613 - 619